# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Robyn Karnauskas maintains Biogen (NASDAQ:BIIB) with a Buy and maintains $340 price target.
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on k...
LEQEMBI is now approved in the U.S., Japan and China, and applications have been submitted for review in the European Union, Au...
Jim Cramer recommends buying Micron, adding that he likes the company's CEO Sanjay Mehrotra. As for Fidelis? "Not a fav...
HSBC analyst Morten Herholdt maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $339 to $342.
Oppenheimer analyst Jay Olson maintains Biogen (NASDAQ:BIIB) with a Outperform and maintains $270 price target.